by Truveta staff | Apr 1, 2025 | Research
GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
by Truveta staff | Jan 9, 2025 | Data
In the world of medical research, data drives discovery. But until recently, nearly 80% of data relevant to research has been hidden in clinical notes. These notes include detailed observations, symptoms, and treatment plans that are absent from the structured data...
by Truveta News | Jan 9, 2025 | News
Truveta was named a gold winner in Most Innovative Company of the Year for medium-sized companies (100-999 employees) in the Best in Biz Awards 2024, the only independent business awards program judged by editors and reporters from North American publications. The...
by Jay Nanduri | Dec 10, 2024 | Technology
In the final article in this series, I will share some thoughts on meeting the following challenge: How to rapidly support new AI scenarios and adjacencies through reuse and transfer learning? Truveta has diverse, multimodal, and up-to-date data on clinical...
by Jay Nanduri | Oct 28, 2024 | Technology
In the journey toward advancing healthcare research, trust in AI tools is essential. Truveta is committed to not only delivering powerful AI-driven data insights but also ensuring transparency, quality, and speed for researchers. A significant part of this commitment...